| Literature DB >> 28195196 |
Nandita Bodra1,2,3,4,5, David Young1,2,3, Leonardo Astolfi Rosado1,2,3, Anna Pallo1,2,3, Khadija Wahni1,2,3, Frank De Proft6, Jingjing Huang1,2,3,4,5, Frank Van Breusegem4,5, Joris Messens1,2,3.
Abstract
Dehydroascorbate reductase (DHAR) catalyzes the glutathione (GSH)-dependent reduction of dehydroascorbate and plays a direct role in regenerating ascorbic acid, an essential plant antioxidant vital for defense against oxidative stress. DHAR enzymes bear close structural homology to the glutathione transferase (GST) superfamily of enzymes and contain the same active site motif, but most GSTs do not exhibit DHAR activity. The presence of a cysteine at the active site is essential for the catalytic functioning of DHAR, as mutation of this cysteine abolishes the activity. Here we present the crystal structure of DHAR2 from Arabidopsis thaliana with GSH bound to the catalytic cysteine. This structure reveals localized conformational differences around the active site which distinguishes the GSH-bound DHAR2 structure from that of DHAR1. We also unraveled the enzymatic step in which DHAR releases oxidized glutathione (GSSG). To consolidate our structural and kinetic findings, we investigated potential conformational flexibility in DHAR2 by normal mode analysis and found that subdomain mobility could be linked to GSH binding or GSSG release.Entities:
Year: 2017 PMID: 28195196 PMCID: PMC5307357 DOI: 10.1038/srep42494
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Reaction scheme for the catalytic cycle of DHA reduction by DHAR2.
In a mechanistic scheme, the ping-pong mechanism for the enzymatic reduction of DHA is shown. DHAR2 is sulfenylated at the catalytic cysteine (Cys20) and GSH performs a nucleophilic attack on the sulfenylated Cys20 to form a mixed disulfide, DHAR2-S-SG (step 1). A second GSH molecule reacts with the mixed disulfide, producing GSSG and the cysteine is released in its reduced thiolate form (step 2). DHA enters the active site of the reduced form of DHAR2 and is converted to AsA (step 3).
Figure 2Reversed-phase fluorescence elution profile of the glutathione-monobromobimane (GS-mBBr) derivatives.
Fluorescence peaks were assigned according to known standards. GSH was alkylated prior to reduction of GSSG, therefore, no mBBr derivatization of the GSH substrate was observed, as shown by the negative control of 6.3 nmol GSH-N-ethylmaleamide (NEM) (grey trace). AtDHAR2-SG without addition of free GSH was used as a negative control (black trace). Concentrations are given as final molar values for the total injected sample. A full elution trace is available in the Supporting information (Fig. S6).
Figure 3Pre-steady-state and steady-state kinetics of AtDHAR2.
(A) Stopped-flow analysis of the reaction of GSH with AtDHAR2:GSH. A linear dependence of the observable rate constants allowed the calculation of a second-order rate constant of 1331 ± 13 M−1 s−1 for the conversion of S-glutathionylated DHAR2 to its reduced form. (B) A sigmoidal rate variance with respect to GSH concentrations with a fixed saturated concentration of DHA (200 μM), represented as a rate constant k (s−1) versus the GSH concentration in mM.
Figure 4Crystal structure of the GSH-bound AtDHAR2.
The N-terminal thioredoxin-like domain (blue) and the C-terminal helical domain (green) are shown.
Figure 5Schematic representation of the G-site GSH environment in AtDHAR2.
The bonding environment of GSH at the G-site of AtDHAR2 is displayed in LIGPLOT (left panel) and PyMOL (right panel)36. H-bonding and salt bridge interactions are illustrated in LIGPLOT by blue dashed lines. The mF-DF omit map for GSH is defined by a blue mesh contoured at 3σ. Waters interacting with GSH are omitted.